Sorafenib for the treatment of recurrent hepatocellular carcinoma after liver transplantation?

Transplantation Proceedings

Volumn 44, Issue 7, 2012, Pages 1989-1991

  Vitale, A ^a   Boccagni, P ^a   Kertusha, X ^a   Zanus, G ^a   D'Amico, F ^a   Lodo, E ^a   Pastorelli, D ^b   Ramirez Morales, R ^b   Lombardi, G ^b   Senzolo, M ^a   Burra, P ^a   Cillo, U ^a  

^a UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^b VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EVEROLIMUS; EXEROLINUS; LOPERAMIDE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; SORAFENIB; TACROLIMUS; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; CANCER GROWTH; CANCER STAGING; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; DIARRHEA; DRUG SAFETY; FATIGUE; FEMALE; GOOD GENERAL CONDITION; HAND FOOT SYNDROME; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FUNCTION; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MALE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECURRENT CANCER; SURVIVAL TIME; TREATMENT DURATION; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; PYRIDINES; RECURRENCE;

EID: 84866307809     PISSN: 00411345     EISSN: 18732623     Source Type: Journal    
DOI: 10.1016/j.transproceed.2012.06.046     Document Type: Conference Paper

References (15)

1. S. Roayaie, J.D. Schwartz, M.W. Sung Recurrence of hepatocellular carcinoma after liver transplant: patterns and prognosis Liver Transpl 10 2004 534
2. M. Schwartz, S. Roayaie, J. Llovet How should patients with hepatocellular carcinoma recurrence after liver transplantation be treated? J Hepatol 43 2005 584
3. E. Davis, R. Wiesner, J. Valdecasas Treatment of recurrent hepatocellular carcinoma after liver transplantation Liver Transpl 17 2011 162
4. J.O. Lee, D.Y. Kim, J.H. Lim Palliative chemotherapy for patients with recurrent hepatocellular carcinoma after liver transplantation J Gastroenterol Hepatol 24 2009 800
5. J.M. Llovet, S. Ricci, V. Mazzaferro Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 2008 378
6. J. Bruix, M. Sherman American Association for the Study of Liver Diseases Management of hepatocellular carcinoma: an update Hepatology 53 2011 1020
7. R. Kim, G. El-Gazzaz, A. Tan Safety and feasibility of using sorafenib in recurrent hepatocellular carcinoma after orthotopic liver transplantation Oncology 79 2010 62
8. A. Valdivieso, J. Bustamante, M. Gastaca Management of hepatocellular carcinoma recurrence after liver transplantation Transplant Proc 42 2010 660
9. O. Waidmann, W.P. Hofmann, S. Zeuzem mTOR inhibitors and sorafenib for recurrent heptocellular carcinoma after orthotopic liver transplantation J Hepatol 54 2011 396
10. T. Takahara, H. Nitta, Y. Hasegawa Using sorafenib for recurrent hepatocellular carcinoma after liver transplantation-interactions between calcineurin inhibitor: two case reports Transplant Proc 43 2011 2800
11. C. Gomez-Martin, J. Bustamante, J.F. Castroagudin et al. Efficacy and safety of sorafenib in combination with mTOR inhibitors in recurrent hepatocarcinoma after liver transplant Liver Transpl 2011
12. M. Vivarelli, A. Cucchetti, F. Piscaglia Analysis of risk factors for tumor recurrence after liver transplantation for hepatocellular carcinoma: key role of immunosuppression Liver Transpl 11 2005 497
13. M.A. Worns, A. Weinmann, K. Pfingst Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis J Clin Gastroenterol 43 2009 489
14. A. Trotti, A.D. Colevas, A. Setser CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment Semin Radiat Oncol 13 2003 176
15. R. Lencioni, J.M. Llovet Modified RECIST (mRECIST) assessment for hepatocellular carcinoma Semin Liver Dis 30 2010 52